

References 1

- American Academy of Family Physicians. (2020). *Assessment and Diagnosis*. Aafp.org.
<https://www.aafp.org/family-physician/patient-care/prevention-wellness/emotional-wellbeing/adhd-toolkit/assessment-and-diagnosis.html>
- Childress, A. C. (2021). Novel Formulations of ADHD Medications: Stimulant Selection and Management. *FOCUS*, 19(1), 31–38. <https://doi.org/10.1176/appi.focus.20200032>
- NHS. (2024). *Medication for ADHD (Attention Deficit Hyperactivity Disorder)*. NHS.
<https://bedslutonchildrenshealth.nhs.uk/neurodiversity-support/adhd-attention-deficit-hyperactivity-disorder/medication-for-adhd-attention-deficit-hyperactivity-disorder/>
- Stevens, J. R., Wilens, T. E., & Stern, T. A. (2013). Using Stimulants for Attention-Deficit/Hyperactivity Disorder. *The Primary Care Companion for CNS Disorders*, 15(2). <https://doi.org/10.4088/pcc.12f01472>
- Substance Abuse and Mental Health Services Administration. (2016). *Table 7, DSM-IV to DSM-5 attention-deficit/hyperactivity disorder comparison*. Nih.gov; Substance Abuse and Mental Health Services Administration (US).
<https://www.ncbi.nlm.nih.gov/books/NBK519712/table/ch3.t3/>
- Verghese, C., & Abdijadid, S. (2024, October 29). *Methylphenidate*. Nih.gov; StatPearls Publishing.
<https://www.ncbi.nlm.nih.gov/books/NBK482451/>
- Vilus, J. T., & Engelhard, C. (2025). Nonstimulant Medications for Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. *Pediatric Annals*, 54(1).
<https://doi.org/10.3928/19382359-20241007-07>

References 2 & 9

- Arnold, E. (2022, June 23). *Anxiety DSM-5 Criteria and Treatment Overview*.
Www.medcentral.com.
<https://www.medcentral.com/behavioral-mental/anxiety/assessment-diagnosis-adherence-anxiety>
- Bains, N., & Abdijadid, S. (2023, April 10). *Major depressive disorder*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK559078/>
- Barch, D. M. (2010). *Schizophrenia Spectrum Disorders*. Noba.
<https://nobaproject.com/modules/schizophrenia-spectrum-disorders>

- Beaulieu, A. M., Tabasky, E., & Osser, D. N. (2019). The psychopharmacology algorithm project at the Harvard South Shore Program: An algorithm for adults with obsessive-compulsive disorder. *Psychiatry Research*, 281, 112583.
<https://doi.org/10.1016/j.psychres.2019.112583>
- Bhattacharya, A., DeFilipp, L., & Timko, C. A. (2020). Feeding and eating disorders. *Handbook of Clinical Neurology*, 175, 387–403. <https://doi.org/10.1016/B978-0-444-64123-6.00026-6>
- Fariba, K., Gupta, V., & Kass, E. (2024). *Personality disorder*. PubMed; StatPearls Publishing.
<https://www.ncbi.nlm.nih.gov/books/NBK556058/>
- Griswold, K. S., Regno, P. a. D., & Berger, R. C. (2015). Recognition and Differential Diagnosis of Psychosis in Primary Care. *American Family Physician*, 91(12), 856–863.
<https://www.aafp.org/pubs/afp/issues/2015/0615/p856.html>
- Jain, A., & Mitra, P. (2023, February 20). *Bipolar Disorder*. PubMed; StatPearls Publishing.
<https://www.ncbi.nlm.nih.gov/books/NBK558998/>
- Lindvall Dahlgren, C., Wisting, L., & Rø, Ø. (2017). Feeding and eating disorders in the DSM-5 era: a systematic review of prevalence rates in non-clinical male and female samples. *Journal of Eating Disorders*, 5(1). <https://doi.org/10.1186/s40337-017-0186-7>
- National Collaborating Centre for Mental Health (UK). (2006). Diagnostic criteria. In www.ncbi.nlm.nih.gov. British Psychological Society.
<https://www.ncbi.nlm.nih.gov/books/NBK56452/>
- Olson, L., Bishop, S., & Thurm, A. (2024). Differential Diagnosis of Autism and Other Neurodevelopmental Disorders. *Pediatric Clinics of North America*.
<https://doi.org/10.1016/j.pcl.2023.12.004>
- Sekhon, S., & Gupta, V. (2023). *Mood Disorder*. PubMed; StatPearls Publishing.
<https://www.ncbi.nlm.nih.gov/books/NBK558911/>
- Substance Abuse and Mental Health Services Administration. (2016). *Table 3.15, DSM-IV to DSM-5 Generalized Anxiety Disorder Comparison*. National Library of Medicine; Substance Abuse and Mental Health Services Administration (US).
<https://www.ncbi.nlm.nih.gov/books/NBK519704/table/ch3.t15/>
- Substance Abuse and Mental Health Services Administration. (2019a). *Impact of the DSM-IV to DSM-5 Changes on the National Survey on Drug Use and Health*. Nih.gov; Substance

Abuse and Mental Health Services Administration (US).

<https://www.ncbi.nlm.nih.gov/books/NBK519704/table/ch3.t22/>

Substance Abuse and Mental Health Services Administration. (2019b, June). *Table 12, DSM-IV to DSM-5 Bipolar I Disorder Comparison*. Nih.gov; Substance Abuse and Mental Health Services Administration (US).

<https://www.ncbi.nlm.nih.gov/books/NBK519712/table/ch3.t8/>

Substance Abuse and Mental Health Services Administration. (2020, June). *DSM-IV to DSM-5 Major Depressive Episode/Disorder Comparison*. Nih.gov; Substance Abuse and Mental Health Services Administration (US).

<https://www.ncbi.nlm.nih.gov/books/NBK519712/table/ch3.t5/>

References 3

Balaram, K., & Marwaha, R. (2023). *Agoraphobia*. National Library of Medicine; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK554387/>

Cleveland Clinic. (2022, April 10). *Social anxiety disorder: Symptoms, tests, causes & treatments*. Cleveland Clinic. <https://my.clevelandclinic.org/health/diseases/22709-social-anxiety>

DeGeorge, K. C., Grover, M., & Streeter, G. S. (2022). Generalized anxiety disorder and panic disorder in adults. *American Family Physician*, 106(2), 157–164. <https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html>

Melaragno, A. J. (2021). Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance. *FOCUS*, 19(2), 145–160. <https://doi.org/10.1176/appi.focus.20200048>

Pull, C. (2008). Pharmacotherapy of panic disorder. *Neuropsychiatric Disease and Treatment*, 779. <https://doi.org/10.2147/ndt.s1224>

Sapra, A., Bhandari, P., Sharma, S., Chanpura, T., & Lopp, L. (2020). Using generalized anxiety disorder-2 (GAD-2) and GAD-7 in a primary care setting. *Cureus*, 12(5), e8224. <https://doi.org/10.7759/cureus.8224>

Sheffler, Z. M., Abdijadid, S., & Patel, P. (2023, May 26). *Antidepressants*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK538182/>

Strawn, J. R., Geraciotti, L., Rajdev, N., Clemenza, K., & Levine, A. (2020). Pharmacotherapy for Generalized Anxiety Disorder in Adult and Pediatric patients: an evidence-based Treatment Review. *Expert Opinion on Pharmacotherapy*, 19(10), 1057–1070.

<https://doi.org/10.1080/14656566.2018.1491966>

Substance Abuse and Mental Health Services Administration. (2016a). *Table 3.15, DSM-IV to DSM-5 Generalized Anxiety Disorder Comparison*. National Library of Medicine; Substance Abuse and Mental Health Services Administration (US).

<https://www.ncbi.nlm.nih.gov/books/NBK519704/table/ch3.t15/>

Substance Abuse and Mental Health Services Administration. (2016b, June). *Table 3.10, Panic Disorder and Agoraphobia Criteria Changes from DSM-IV to DSM-5*. National Library of Medicine; Substance Abuse and Mental Health Services Administration (US).

<https://www.ncbi.nlm.nih.gov/books/NBK519704/table/ch3.t10/>

References 4

Bielecki, J. E., & Gupta, V. (2023, July 17). *Cyclothymic Disorder*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK557877/>

Jain, A., & Mitra, P. (2023, February 20). *Bipolar Disorder*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK558998/>

Shen, Y.-C. (2018). Treatment of acute bipolar depression. *Tzu-Chi Medical Journal*, 30(3), 141–147. https://doi.org/10.4103/tcmj.tcmj_71_18

Substance Abuse and Mental Health Services Administration. (2016, June). *Table 3.23, DSM-IV to DSM-5 Bipolar II Disorder Comparison*. Nih.gov; Substance Abuse and Mental Health Services Administration (US).

<https://www.ncbi.nlm.nih.gov/books/NBK519704/table/ch3.t23/>

Substance Abuse and Mental Health Services Administration. (2019, June). *Table 12, DSM-IV to DSM-5 Bipolar I Disorder Comparison*. Nih.gov; Substance Abuse and Mental Health Services Administration (US).

<https://www.ncbi.nlm.nih.gov/books/NBK519712/table/ch3.t8/>

Vieta, E., & Sanchez-Moreno, J. (2008). Acute and long-term treatment of mania. *Developments in Bipolar Disorder*, 10(2), 165–179. <https://doi.org/10.31887/dcns.2008.10.2/evieta>

References 5

- Bains, N., & Abdijadid, S. (2023, April 10). *Major depressive disorder*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK559078/>
- Karrouri, R., Hammani, Z., Benjelloun, R., & Otheman, Y. (2021). Major Depressive disorder: Validated Treatments and Future Challenges. *World Journal of Clinical Cases*, 9(31), 9350–9367. <https://doi.org/10.12998/wjcc.v9.i31.9350>
- Preskorn, S. H., & Burke, M. (1992). Somatic therapy for major depressive disorder: selection of an antidepressant. *The Journal of Clinical Psychiatry*, 53 Suppl, 5–18. <https://pubmed.ncbi.nlm.nih.gov/1522080/>
- Substance Abuse and Mental Health Services Administration. (2020, June). *DSM-IV to DSM-5 Major Depressive Episode/Disorder Comparison*. Nih.gov; Substance Abuse and Mental Health Services Administration (US). <https://www.ncbi.nlm.nih.gov/books/NBK519712/table/ch3.t5/>

References 6

- 2025 ICD-10-CM Codes F60-F69: Disorders of adult personality and behavior. (2025). Icd10data.com. <https://www.icd10data.com/ICD10CM/Codes/F01-F99/F60-F69>
- ICD-10. (2016). *ICD-10 Version:2016*. Who.int. <https://icd.who.int/browse10/2016/en#>
- ICD-10 | Phobic anxiety disorders (F40). (2024). Purdue.edu. <https://cdek.pharmacy.purdue.edu/icd10/F40/>
- ICD-10 Version:2014. (n.d.). Icd.who.int. <https://icd.who.int/browse10/2014/en#>
- ICD-10 Version:2014. (2019). Who.int. <https://icd.who.int/browse10/2014/en#/F40-F48>
- ICD-10 Version:2016. (n.d.). Icd.who.int. <https://icd.who.int/browse10/2016/en#/F50-F59>
- ICD-10 Version:2019. (2019). Icd.who.int. <https://icd.who.int/browse10/2019/en#/F30-F39>
- The ICD-10 Classification of Mental and Behavioural Disorders Clinical descriptions and diagnostic guidelines*. (n.d.). https://iris.who.int/bitstream/handle/10665/37958/9241544228_eng.pdf

References 7

- American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders. Diagnostic and Statistical Manual of Mental Disorders*, 5(5). <https://doi.org/10.1176/appi.books.9780890425596>

- Bhandal, K. (2025). *Medical Conditions That Mimic Psychiatric Illnesses*. Thecarlatreport.com; CARLAT PUBLISHING. <https://www.thecarlatreport.com/articles/4976-medical-conditions-that-mimic-psychiatric-illnesses>
- Crouch, M. (2022, March 21). *These Problems Can Mimic Dementia*. AARP. <https://www.aarp.org/health/conditions-treatments/medical-problems-mimic-dementia/>
- Crouch, M. (2024, January 24). *9 Conditions That Seem Like Depression but Aren't*. AARP. <https://www.aarp.org/health/healthy-living/conditions-that-mimic-depression/>
- Ferguson, S. (2024, August). *10 Medical Conditions That Mimic the Symptoms of Anxiety*. Healthline; Healthline Media. <https://www.healthline.com/health/medical-conditions-that-mimic-anxiety>
- Pagán, C. N. (2023). *Conditions That Can Seem Like Schizophrenia*. WebMD. <https://www.webmd.com/schizophrenia/schizophrenia-conditions-that-can-seem-like>
- Robinson, K. M. (2021, July 8). *Things That Look Like Depression but Aren't*. WebMD. <https://www.webmd.com/depression/looks-like-depression-but-not>
- Slivinski, N. (2023, March 17). *Conditions That Look Like Anxiety*. WebMD. <https://www.webmd.com/anxiety-panic/ss/slideshow-conditions-that-look-like-anxiety>

References 8

- Brock, H., Hany, M., & Rizvi, A. (2024). *Obsessive-Compulsive Disorder (OCD)*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK553162/>
- CDC. (2024, September 26). *Obsessive-Compulsive Disorder in Children*. Children's Mental Health. <https://www.cdc.gov/children-mental-health/about/obsessive-compulsive-disorder-in-children.html>
- International OCD Foundation. (2025, June 2). *OCD Treatment Guide: Best Evidence-Based Therapies, Medications, and New Advances*. International OCD Foundation. <https://iocdf.org/ocd-treatment-guide/>
- Pampaloni, I., Marriott, S., Pessina, E., Fisher, C., Govender, A., Mohamed, H., Chandler, A., Tyagi, H., Morris, L., & Pallanti, S. (2022). The global assessment of OCD. *Comprehensive Psychiatry*, 118(152342), 152342. <https://doi.org/10.1016/j.comppsy.2022.152342>

Pittenger, C., & Bloch, M. H. (2014). Pharmacological Treatment of Obsessive-Compulsive Disorder. *Psychiatric Clinics of North America*, 37(3), 375–391.

<https://doi.org/10.1016/j.psc.2014.05.006>

Substance Abuse and Mental Health Services Administration. (2021, June). *Table 3.13, DSM-IV to DSM-5 Obsessive-Compulsive Disorder Comparison*. Nih.gov; Substance Abuse and Mental Health Services Administration (US).

<https://www.ncbi.nlm.nih.gov/books/NBK519704/table/ch3.t13/>

Torres, A. R., Fontenelle, L. F., Shavitt, R. G., Ferrão, Y. A., do Rosário, M. C., Storch, E. A., & Miguel, E. C. (2016). Comorbidity variation in patients with obsessive–compulsive disorder according to symptom dimensions: Results from a large multicentre clinical sample. *Journal of Affective Disorders*, 190, 508–516.

<https://doi.org/10.1016/j.jad.2015.10.051>

References 10

American Psychological Association. (2017). PTSD Assessment Instruments.

<https://www.apa.org>. <https://www.apa.org/ptsd-guideline/assessment>

Angelakis, S., Weber, N., & Nixon, R. D. V. (2020). Comorbid posttraumatic stress disorder and major depressive disorder: The usefulness of a sequential treatment approach within a randomised design. *Journal of Anxiety Disorders*, 76, 102324.

<https://doi.org/10.1016/j.janxdis.2020.102324>

Brady, K. T., Killeen, T. K., Brewerton, T., & Lucerini, S. (2000). Comorbidity of psychiatric disorders and posttraumatic stress disorder. *The Journal of Clinical Psychiatry*, 61(7), 22–32. <https://pubmed.ncbi.nlm.nih.gov/10795606/>

Center for Substance Abuse Treatment (US). (2019). *DSM-5 diagnostic criteria for PTSD*. National Library of Medicine; Substance Abuse and Mental Health Services Administration (US).

https://www.ncbi.nlm.nih.gov/books/NBK207191/box/part1_ch3.box16/

Fariba, K., & Gupta, V. (2024, April 20). *Posttraumatic Stress Disorder In Children*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK559140/>

Mann, S. K., Marwaha, R., & Torrico, T. J. (2024). *Posttraumatic stress disorder (PTSD)*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK559129/>

Mayo Clinic. (2024). *Post-traumatic stress disorder (PTSD) - diagnosis and treatment - mayo clinic*. Mayoclinic.org; Mayo Clinic.
<https://www.mayoclinic.org/diseases-conditions/post-traumatic-stress-disorder/diagnosis-treatment/drc-20355973>

Schrader, C., & Ross, A. (2021). A Review of PTSD and Current Treatment Strategies. *Missouri Medicine*, 118(6), 546–551. <https://pmc.ncbi.nlm.nih.gov/articles/PMC8672952/>

References 11

Chien, W. T., Leung, S. F., Yeung, F. K., & Wong, W. K. (2013). Current Approaches to Treatments for Schizophrenia Spectrum disorders, Part II: Psychosocial Interventions and patient-focused Perspectives in Psychiatric Care. *Neuropsychiatric Disease and Treatment*, 9(9), 1463. <https://doi.org/10.2147/ndt.s49263>

Hany, M., Rehman, B., Azhar, Y., & Chapman, J. (2024, February 23). *Schizophrenia*. NIH.gov; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK539864/>

Harrison, J., Mcilwain, M., Wheeler, & Russell. (2011). Pharmacotherapy for treatment-resistant schizophrenia. *Neuropsychiatric Disease and Treatment*, 135.
<https://doi.org/10.2147/ndt.s12769>

Kumari, S., Malik, M., Florival, C., Manalai, P., & Sonje, S. (2017). An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS). *Journal of Addiction Research & Therapy*, 08(03). <https://doi.org/10.4172/2155-6105.1000324>

Malaspina, D., Owen, M. J., Heckers, S., Tandon, R., Bustillo, J., Schultz, S., Barch, D. M., Gaebel, W., Gur, R. E., Tsuang, M., Van Os, J., & Carpenter, W. (2013). Schizoaffective Disorder in the DSM-5. *Schizophrenia Research*, 150(1), 21–25.
<https://doi.org/10.1016/j.schres.2013.04.026>

Patel, K. R., Cherian, J., Gohil, K., & Atkinson, D. (2014). Schizophrenia: Overview and Treatment Options. *Pharmacy and Therapeutics*, 39(9), 638.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC4159061/>

Substance Abuse and Mental Health Services Administration. (2019). *Impact of the DSM-IV to DSM-5 Changes on the National Survey on Drug Use and Health*. Nih.gov; Substance Abuse and Mental Health Services Administration (US).
<https://www.ncbi.nlm.nih.gov/books/NBK519704/table/ch3.t22/>

Wy, T. J. P., & Saadabadi, A. (2023, March 27). *Schizoaffective Disorder*. Nih.gov; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK541012/>

References 12

Dowell, D. (2024). Treatment for Opioid Use Disorder: Population Estimates — United States, 2022. *MMWR. Morbidity and Mortality Weekly Report*, 73(73).

<https://doi.org/10.15585/mmwr.mm7325a1>

Dydyk, A. M., Jain, N. K., & Gupta, M. (2024). *Opioid Use Disorder*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK553166/>

Fluyau, D., & Charlton, T. E. (2024, January 10). *Addiction*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK549783/>

Gateway Foundation. (2021, June 15). *DSM-5 Criteria for Substance Use Disorders*. Gateway Foundation. <https://www.gatewayfoundation.org/blog/dsm-5-substance-use-disorder/>

Nehring, S. M., & Freeman, A. M. (2024). *Alcohol use disorder*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK436003/>

Patel, J., & Marwaha, R. (2024, March 20). *Cannabis use disorder*. Nih.gov; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK538131/>

Song, W., Simona, A., Zhang, P., Bates, D. W., & Urman, R. D. (2024). Stimulant Drugs and Stimulant Use Disorder. *Anesthesiology Clinics*, 42(1), 103–115.

<https://doi.org/10.1016/j.anclin.2023.09.003>

References 13

Bains, N., & Abdijadid, S. (2023, April 10). *Major depressive disorder*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK559078/>

Beaulieu, A. M., Tabasky, E., & Osser, D. N. (2019). The psychopharmacology algorithm project at the Harvard South Shore Program: An algorithm for adults with obsessive-compulsive disorder. *Psychiatry Research*, 281, 112583.

<https://doi.org/10.1016/j.psychres.2019.112583>

DeGeorge, K. C., Grover, M., & Streeter, G. S. (2022). Generalized anxiety disorder and panic disorder in adults. *American Family Physician*, 106(2), 157–164.

<https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html>

- Eom, T.-H., & Kim, Y.-H. (2023). Clinical Practice Guidelines for Attention-deficit/Hyperactivity Disorder: Recent Updates. *Clinical and Experimental Pediatrics (Online)*, 67(1). <https://doi.org/10.3345/cep.2021.01466>
- H, C. (2011, November 16). *Pharmacotherapy of Major Depressive Disorder*. Uspharmacist.com. <https://www.uspharmacist.com/article/pharmacotherapy-of-major-depressive-disorder>
- Holtzheimer, P., & Montaña, M. (2014). *Clinician's Guide to Medications for PTSD - PTSD: National Center for PTSD*. Va.gov. https://www.ptsd.va.gov/professional/treat/txessentials/clinician_guide_meds.asp
- Implementing the Key Action Statements: An Algorithm and Explanation for Process of Care for the Evaluation, Diagnosis, Treatment, and Monitoring of ADHD in Children and Adolescents*. (n.d.). https://chsciowa.org/sites/chsciowa.org/files/resource/files/3_-_adhd_algorithm_supplement.pdf
- Jain, A., & Mitra, P. (2023, February 20). *Bipolar Disorder*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK558998/>
- Kimmel, R. (2018). *UW PACC Psychiatry and Addictions Case Conference MEDICATION ALGORITHM FOR ANXIETY DISORDERS*. https://ictp.uw.edu/sites/default/files/UWPACC_2018_10_18_Anxiety_An_Algorithm_for_medication_trials_Ryan_Kimmel_MD.pdf
- Kishi, T., Ikuta, T., Matsuda, Y., Sakuma, K., Okuya, M., Nomura, I., Hatano, M., & Iwata, N. (2021). Pharmacological treatment for bipolar mania: A systematic review and network meta-analysis of double-blind randomized controlled trials. *Molecular Psychiatry*, 27(2). <https://doi.org/10.1038/s41380-021-01334-4>
- Kovich, H., Kim, W., & Quaste, A. M. (2023). Pharmacologic Treatment of Depression. *American Family Physician*, 107(2), 173–181. <https://www.aafp.org/pubs/afp/issues/2023/0200/pharmacologic-treatment-of-depression.html>
- Martin, A., Naunton, M., Kosari, S., Peterson, G., Thomas, J., & Christenson, J. K. (2021). Treatment guidelines for PTSD: A systematic review. *Journal of Clinical Medicine*, 10(18). <https://doi.org/10.3390/jcm10184175>

- Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2022). Treatment of ADHD: Drugs, Psychological therapies, devices, Complementary and Alternative Methods as Well as the Trends in Clinical Trials. *Frontiers in Pharmacology*, 13(13), 1–19. <https://doi.org/10.3389/fphar.2022.1066988>
- Patel, K. R., Cherian, J., Gohil, K., & Atkinson, D. (2014). Schizophrenia: Overview and Treatment Options. *Pharmacy and Therapeutics*, 39(9), 638. <https://pmc.ncbi.nlm.nih.gov/articles/PMC4159061/>
- Paxos, C. (2022). Moving beyond first-line treatment options for OCD. *Mental Health Clinician*, 12(5), 300–308. <https://doi.org/10.9740/mhc.2022.10.300>
- Rybakowski, J. K. (2023). Application of Antipsychotic Drugs in Mood Disorders. *Brain Sciences*, 13(3), 414. <https://doi.org/10.3390/brainsci13030414>
- Sartor, Z., Kelley, L., & Laschober, R. (2023). Posttraumatic Stress Disorder: Evaluation and Treatment. *American Family Physician*, 107(3), 273–281. <https://www.aafp.org/pubs/afp/issues/2023/0300/posttraumatic-stress-disorder.html>
- Shah, N., Grover, S., & Rao, Gp. (2020). Clinical practice guidelines for management of bipolar disorder. *Indian Journal of Psychiatry*, 59(5), 51. <https://doi.org/10.4103/0019-5545.196974>